Merck, Lycera broaden partnership on autoimmune disease drugs

Merck & Co. expanded a collaboration with Lycera to develop and market small-molecule drugs against autoimmune diseases. The deal entitles Lycera to an undisclosed upfront fee and research support plus more than $300 million in possible milestone fees, plus royalties. Merck will handle clinical development, and will get the global rights to marketing.

View Full Article in:

Genetic Engineering & Biotechnology News · Crain's Detroit Business (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health